SST and neuroendocrine neoplasm: In this context, this report provides a comprehensive and extensive overview of the development of 225Ac-labeled somatostatin analogs; particular emphasis is placed on the challenges associated with the production of 225Ac, its physical and radiochemical properties, as well as the place of 225Ac–DOTATOC and 225Ac–DOTATATE in the management of patients with advanced metastatic neuroendocrine tumors.